Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received the “Notice of Acceptance” issued by the State Drug Administration, and the company's drug marketing license application for injectable Ruikang Luzetolutamab (SHR-A2009 for injections) was accepted by the State Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.